|
 Covaxin initially had a shelf life of six months when it first
received emergency use approval in the country, which was later
extended to nine months, a company spokeswoman told Reuters.
The company said that the approval is based on the availability of
additional stability data, which was submitted to the Central Drugs
Standard Control Organisation.
The Indian drug regulator's extension approval comes shortly ahead
of a much awaited decision from the World Health Organization (WHO)
regarding Covaxin's addition for emergency use listing.
The pending WHO approval has left millions of Indians, who have
received the homegrown shot, contemplating foreign trips as most
countries rely on the WHO nod for allowing international travellers.
[to top of second column] |
 The WHO's advisory group was
expected to make a decision on Covaxin last
week, but asked for additional clarifications
from Bharat Biotech before conducting a final
risk-benefit assessment for the vaccine's global
use.
(Reporting by Shivani Singh and Chandini
Monnappa in Bengaluru; Editing by Anil D'Silva
and Shailesh Kuber)
[© 2021 Thomson Reuters. All rights
reserved.] Copyright 2021 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content |
